|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 325 7th Street NW, 9th Floor |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 31348-12
|
||||||||
|
6. House ID# 340040000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Brenda Palmer |
Date | 1/21/2021 4:58:01 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to prescription drug coverage and pharmacy benefits
H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act
H.R.1034/S.640: Phair Pricing Act of 2019
H.R.1035: Prescription Drug Price Transparency Act
H.R.5800: Ban Surprise Billing Act
S.2543: Prescription Drug Pricing Reduction Act
S.2247: Phair Relief Act
Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits
H.R.19/S.3129: Lower Costs More Cures Act
H.R.2279/S.2546: Safe Step Act
H.R.3: Lower Drug Costs Now Act
H.R. 6557 MAIL Act
S.3384: Lowering Prescription Drug Prices for America's Seniors and Families Act
S.3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
Executive Order on An America-First Healthcare Plan
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen
42 CFR Part 1001 RIN 0936-AA08: Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Prescription drug pricing transparency
H.R.1264/S.801: Payment Commission Data Act
H.R.223/S.532: PBM Study Act
H.R.1781: Payment Commission Data Act
H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act
H.R.2115: Public Disclosure of Drug Discounts Act
H.R.5304: PBM Transparency in Prescription Drug Costs Act
H.R.133: Consolidated Appropriations Act, 2021
S.476: C-THRU Act
S.2543: Prescription Drug Pricing Reduction Act
Access to prescription drugs during the coronavirus pandemic
H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act
H.R.6557: MAIL Act
H.R.6800: HEROES Act
Generic and biosimilar utilization
H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
JC |
Scott |
|
|
|
Kristin |
Bass |
|
|
|
Jonathan |
Heafitz |
|
|
|
Katherine |
Murphy |
|
|
|
Jocelyn |
Wiles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to prescription drug coverage and pharmacy benefits
H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act
H.R.1034/S.640: Phair Pricing Act of 2019
H.R.1035: Prescription Drug Price Transparency Act
H.R.5800: Ban Surprise Billing Act
S.2543: Prescription Drug Pricing Reduction Act
S.2247: Phair Relief Act
S.1895: Lower Health Care Costs Act
Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market
Prescription drug pricing transparency
H.R.1264/S.801: Payment Commission Data Act
H.R.2376/S.1227: Prescription Pricing for the People Act
H.R.3223/S.1532 PBM Study Act
H.R.1781: Payment Commission Data Act
H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act
H.R.2115: Public Disclosure of Drug Discounts Act
H.R.5304: PBM Transparency in Prescription Drug Costs Act
H.R.133: Consolidated Appropriations Act, 2021
S.476: C-THRU Act
S.2543: Prescription Drug Pricing Reduction Act
S.657: Drug Price Transparency Act
S.977: Transparent Drug Pricing Act
Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits
H.R.19/S.3129:Lower Costs More Cures Act
H.R.2279/S.2546: Safe Step Act
H.R.6557: MAIL Act
H.R.3: Lower Drug Costs Now Act
S.3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S.3384: Lowering Prescription Drug Prices for America's Seniors and Families Act
Executive Order on An America-First Healthcare Plan
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen
42 CFR Part 1001 RIN 0936-AA08: Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Access to prescription drugs during the coronavirus pandemic
H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act
H.R.6557 MAIL Act
H.R.6800: HEROES Act
Generic and biosimilar utilization
H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes (McKinley)
Issues related to prescription drug patents and approval process
H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act
H.R.985: Fair Access for Safe and Timely (FAST) Generics Act
H.R.1499: Protecting Consumer Access to Generic Drugs Act
H.R.1520: Purple Book Continuity Act
H.R.1503: Orange Book Transparency Act
S.64: Preserve Access to Affordable Generics and Biosimilars Act
S.659: Biologic Patent Transparency Act
Issues related to coverage of prescription drugs in the commercial market
H.R.5304: PBM Transparency in Prescription Drug Costs Act
H.R.5800: Ban Surprise Billing Act
S.657: Drug Price Transparency Act
S.977: Transparent Drug Pricing Act
S.1895: Lower Health Care Costs Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Executive Office of the President (EOP), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
JC |
Scott |
|
|
|
Kristin |
Bass |
|
|
|
Jonathan |
Heafitz |
|
|
|
Katherine |
Murphy |
|
|
|
Jocelyn |
Wiles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks
H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act
H.R.1034/S.640: Phair Pricing Act of 2019
H.R.1035: Prescription Drug Price Transparency Act
H.R.5800: Ban Surprise Billing Act
S.2543: Prescription Drug Pricing Reduction Act
S.2247: Phair Relief Act
S.1895: Lower Health Care Costs Act
Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy
Prescription drug pricing transparency
H.R.2376/S.1227: Prescription Pricing for the People Act
H.R.3223/S.1532: PBM Study Act
H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act
H.R.2115: Public Disclosure of Drug Discounts Act
H.R.5304: PBM Transparency in Prescription Drug Costs Act
H.R.133: Consolidated Appropriations Act, 2021
S.476: C-THRU Act
S.2543: Prescription Drug Pricing Reduction Act
S.657: Drug Price Transparency Act
S.977: Transparent Drug Pricing Act
Regulatory and proposed legislative changes to Medicare Part D
H.R.19/S.3129: Lower Costs More Cures Act
H.R.3: Lower Drug Costs Now Act
S.3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S.3384: Lowering Prescription Drug Prices for America's Seniors and Families Act
Executive Order on An America-First Healthcare Plan
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen
42 CFR Part 1001 RIN 0936-AA08: Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Access to prescription drugs during the coronavirus pandemic
H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act
H.R.6557: MAIL Act
H.R.6800: HEROES Act
Generic and biosimilar utilization
H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes (McKinley)
Issues related to coverage of prescription drugs in the commercial market
H.R.5304: PBM Transparency in Prescription Drug Costs Act
H.R.5800: Ban Surprise Billing Act
S.657: Drug Price Transparency Act
S.977: Transparent Drug Pricing Act
S.1895: Lower Health Care Costs Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
JC |
Scott |
|
|
|
Kristin |
Bass |
|
|
|
Jonathan |
Heafitz |
|
|
|
Katherine |
Murphy |
|
|
|
Jocelyn |
Wiles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code POS
16. Specific lobbying issues
Issues related to the use of the United States Postal Service (USPS) for prescription drug home delivery
H.R.8123/S.4174: Postal Service Emergency Assistance Act
H.R.133: Consolidated Appropriations Act, 2021
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
JC |
Scott |
|
|
|
Kristin |
Bass |
|
|
|
Jonathan |
Heafitz |
|
|
|
Katherine |
Murphy |
|
|
|
Jocelyn |
Wiles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |